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1. Introduction 
Turmeric, derived from the plant Curcuma longa, is a gold-
colored spice commonly used in the Indian subcontinent, not only for 
health care but also for the preservation of food and as a yellow dye 
for textiles. Curcumin, which gives the yellow color to turmeric, since 
the time of Ayurveda numerous therapeutic activities have been 
assigned to turmeric for a wide variety of diseases and conditions, 
including those of the skin, pulmonary, and gastrointestinal systems, 
aches, pains, wounds, sprains, and liver disorders. Extensive research 
within the last half century has proven that most of these activities, 
once associated with turmeric, are due to curcumin. Curcumin has 
been shown to exhibit antiviral [1,2], antibacterial [3], anti-fungal [4], 
antimalarial [5,6], antiparasitic [7-10], anti-AIDS [11], antidepressant 
[12.13], anti-spasmodic [14], antivenomic [15], antiatherosclerosis 
[16], contraceptive [17], anticataract [18,19], anti-cyctic fibrosis 
[20,21], antiepilepsy [22], anti-hyalinen membrane disease (HMD) 
[23], antihypolipidemic [24], hepatoprotectives [25], effective in lung 
disease [26], antiosteoprosis [27], antiparkinson [28] and effective in 
renal diseases [29-31] etc. curcumin also exhibited antioxidant, anti-
inflammatory, anticancer activities and thus has a potential against 
various malignant diseases, diabetes, allergies, arthritis, Alzheimer’s 
disease, and other chronic illnesses. These effects are mediated 
through the regulation of various transcription factors, growth 
factors, inflammatory cytokines, protein kinases, and other enzymes. 
Curcumin exhibits activities similar to recently discovered tumor 
necrosis factor blockers, a vascular endothelial cell growth factor 
blocker, and human epidermal growth factor receptor blockers. 
Considering the recent scientific band wagon that multi targeted 
therapy is better than mono targeted therapy for most diseases [32-
40]. 
Curcumin is one such medicine. Its history goes back over 
5000 years, to the heyday of Ayurveda (which means the science of 
long life). Turmeric derived from the rhizome of the plant Curcuma 
longa has been used by the people of the Indian subcontinent for 
centuries with no known side effects, not only as a component of food 
but also to treat a wide variety of ailments. Turmeric is a spice of 
golden color that is used in cooking in the Indian subcontinent. 
Because of its color and taste, turmeric was named “Indian saffron” in 
Europe. Today, India is the primary exporter of turmeric (known as 
haldi in India). Although its ability to preserve food through its 
antioxidant mechanism, to give color to food, and to add taste to the 
food is well known, its health promoting effects are less well 
recognized or appreciated. It was once considered a cure for jaundice, 
an appetite suppressant, and a digestive. In Indian and Chinese 
medicines, turmeric was used as an anti-inflammatory agent to treat 
gas, colic, toothaches, chest pains, and menstrual difficulties. This 
spice was also used to help with stomach and liver problems, to heal 
wounds and lighten scars, and as a cosmetic. Turmeric was 
mentioned in the writings of Marco Polo concerning his 1280 journey 
to China and India and it was first introduced to Europe in the 13th 
century by Arab traders.  
Although Vasco de Gama (a Portugeese sailor) during 15th 
century, after his visit to India, truly introduced spices to the West, it 
was during the rule of British in India that turmeric was combined 
with various other spices and renamed “curry powder,” as it is called 
in the West. Epilepsy affects approximately 50 million people of 
whom about 40 million people lack appropriate treatment and is 
emerging fast as a hindrance to many lives. On the other hand, the 
abundant side effects of the existing antiepileptic drugs (AEDs) are of 
great concern for both patients and physicians. The long term use of 
traditional medicines for prophylaxis is ruled out in the treatment of 
epilepsy, since the unpredictability of seizure occurrence limits their 
therapeutic efficacy. Furthermore, cognitive defects pose a serious 
threat in epileptic patients and the worsening effects of the existing 
AEDs are anchoring the cognitive deficits of the epileptic patients. 
Although extensive research on the neurobiological bases was 
performed to understand the role of neurochemicals in regulation of 
epilepsy, studies showing the involvement of brain catecholoamines 
and indoleamines in seizure reduction are meager. However, a few 
studies have reported the protective effect of norepinephrine (NE) 
against electroshock induced GTC seizures, and serotonin (5-HT) 
against pentylenetetrazole (PTZ) induced absence seizures, throw 
some light on the role of neurotransmitters in the treatment of 
seizures, involvement of brain monoamines, mainly the NE and 
dopamine (DA), in mediating the cognitive tasks in patients with 
Alzheimer’s disease. Additionally, several publications have provided 
information on seizures and their treatment, although very few 
attempts have been made to study the effect of drugs on memory 
after seizure inductement, the role of monoamines in protection from 
seizure occurrence and memory impairment, and the effect of 
standard AED treatment on memory. In view of these findings, we 
have chosen curcumin–the active constituent of Curcuma longa–
which has been claimed to possess efficacy in the treatment of 
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Alzheimer’s disease , MAO-A & B inhibitory activity enhancement of 
brain monoamine levels, and rhizomes being cited in the database for 
Indian medicinal plants in the treatment of epilepsy, for which no 
reported evidence was available, all these factors had made us to 
focus on the objectives of the present study, to evaluate: 1) the 
protective effect of curcumin on the Maximal electro shock (MES) 
induced seizures; 2) effect on memory retention after seizure 
induction; and 3) effect on the neurotransmitter levels in various 
regions of rat brain [40-56]. 
 
2. Composition of turmeric 
Turmeric contains a wide variety of phytochemicals, 
including curcumin, demethoxycurcumin, bisdemethoxycurcumin, 
zingiberene, curcumenol, curcumol, eugenol, tetrahydro curcumin, 
triethylcurcumin, turmerin, turmerones, and turmeronols. 1) 
Curcumin, demethoxycurcumin, and bisdemethoxycurcumin have 
also been isolated from Curcuma mangga, 2) C. longa, C. cassia C. 
zedoaria, 3) Costus speciosus, 4) C. xanthorrhiza, C. aromatica, 5) C. 
phaeocaulis, Etlingera elatior, 6) and Zingiber cassumunar 7) 
Curcumin is the phytochemical that gives a yellow color to turmeric 
and is now recognized as being responsible for most of the 
therapeutic effects. It is estimated that 2–5% of turmeric is 
curcumin [57,58].  
 
3. Curcumin and its analogues 
Curcumin was first isolated from turmeric in 1815, and 
structure was elucidated in 1910 as diferuloylmethane. Curcumin is 
hydrophobic in nature and frequently soluble in dimethylsulfoxide, 
acetone, ethanol, and oils. When exposed to acidic conditions, the 
color of turmeric/curcumin turns from yellow to deep red, and the 
form in which it is used routinely for various religious ceremonies. 
Turmeric contains three different analogues of curcumin (i.e., 
diferuloylmethane, also called curcumin, demethoxycurcumin, and 
bisdemothycurcumin. Whether all three analogues exhibit equal 
activity is not clear. Although in most systems curcumin was found to 
be most potent, in some systems bisdemethoxycurcumin was found 
to exhibit higher activity. There are also suggestions that the mixture 
of all three is more potent than either one alone. When administered 
orally, curcumin is metabolized into curcumin glucuronide and 
curcumin sulfonate. However, when administered systemically or 
intraperitoneally, it is metabolized into tetrahydrocurcumin, 
hexhyrdrocurcumin, and hexhydrocurcuminol. Tetrahydrocurcumin 
has been shown to be active in some systems and not in others 
[57,58].   
 
4. Uses of curcumin 
The use of turmeric for health purposes is nothing new. As 
a folklore medicine, its use has been documented in both Indian and 
Chinese cultures. The long list of uses include antiseptic, analgesic, 
anti-inflammatory, antioxidant, antimalarial, insect repellant, and 
other activities associated to turmeric.[4,20–27]. Perhaps one of the 
most often prescribed uses is for wound-healing.[28] This activity is 
well known to people from the Indian subcontinent. Modern research 
has provided considerable evidence, and the mechanism by which 
turmeric/curcumin could accelerate wound-healing has been 
described.[29–36] It is now well recognized that most chronic 
diseases are the result of disregulated inflammation,[37,38] Turmeric 
has been traditionally described as an anti-inflammatory agent. 
Recent scientific evidence has indeed demonstrated that turmeric, 
and curcumin in particular, exhibits potent anti-inflammatory 
activities as determined by a wide variety of systems.[39–49] 
Therefore, it is not too surprising that turmeric displays activities 
against a variety of diseases. Because curcumin also exhibits potent 
antioxidant activity, whether the anti-inflammatory activity of 
curcumin is mediated through its antioxidant mechanism is not clear. 
Since most well-characterized antioxidants do not exhibit 
antinflammatory activity, it is unlikely that the anti-inflammatory 





















Figure 1. Chemical structures of curcumin and its analogues 
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5. Disease targets of curcumin 
The research has revealed that curcumin has potential 
against a wide variety of diseases, both malignant and nonmalignant. 
The potential of curcumin, however, has not been systematically 
examined through the modern multicenter, randomized, doubleblind, 
placebo-controlled clinical trial. Its potential in humans is indicated 
either through preclinical studies, some pilot studies in humans, 
anecdotal studies in patients, or epidemiological studies. Curcumin 
has been shown to exhibit activity against numerous inflammatory 
diseases, including pancreatitis, arthritis, inflammatory bowel disease 
(IBD), colitis, gastrititis, allergy, and fever, possibly through the 
downregulation of inflammatory markers, as indicated earlier. The 
effect of curcumin against various autoimmune diseases has also 
been demonstrated; they include scleroderma, psoriasis, multiple 
sclerosis, and diabetes. Again, these effects of curcumin are through 
the regulation of pro-inflammatory signaling. Although once thought 
to be distinct, the molecular targets for both the prevention and 
therapy of cancer are now considered the same. Numerous lines of 
evidence suggest the potential of curcumin against various types of 
cancer. First, curcumin has been shown to suppress the proliferation 
of a wide variety of tumor cells through the down regulation of 
antiapoptotic gene products, activation of caspases, and induction of 
tumor suppressor genes such as. Second, curcumin has also been to 
shown to suppress the invasion of tumors through the down 
regulation of matrix metalloproteinases (MMPs) and cell surface 
adhesion molecules. Third, curcumin suppresses the angiogenesis of 
tumors through the suppression of angiogeneic cytokines. Fourth, the 
anti-inflammatory effects of curcumin contribute to its antitumor 
activity as well. Curcumin has also been shown to play a role in 
diabetes mellitus type II, in which the patient develops a resistance to 
insulin. Several animal studies have demonstrated that curcumin can 
overcome insulin resistance. That curcumin prevents myocardial 
infarction and other cardiovascular diseases has also been 
demonstrated. The effects of curcumin in cardiovascular diseases are 
linked to its ability to inhibit platelet aggregation inhibit 
inflammatory response lower LDL and elevate HDL, inhibit fibrinogen 
synthesis, and inhibit oxidation of LDL. All of these activities 
contribute to the cardiovascular effects of curcumin. Because 
curcumin can suppress amyloid-induced inflammation, curcumin has 
also been linked to the suppression of Alzheimer’s disease [33-56]. 
Epilepsy affects approximately 50 million people of whom 
about 40 million people lack appropriate treatment [59] and is 
emerging fast as a hindrance to many lives. On the other hand, the 
abundant side effects of the existing antiepileptic drugs (AEDs) are of 
great concern for both patients and physicians. The long term use of 
traditional medicines for prophylaxis is ruled out in the treatment of 
epilepsy, since the unpredictability of seizure occurrence limits their 
therapeutic efficacy. Furthermore, cognitive defects pose a serious 
threat in epileptic patients [60] and the worsening effects of the 
existing AEDs are anchoring the cognitive deficits of the epileptic 
patients. Although extensive research on the neurobiological bases 
was performed to understand the role of neurochemicals in 
regulation of epilepsy, studies showing the involvement of brain 
catecholoamines and indoleamines in seizure reduction are meager. 
However, a few studies have reported the protective effect of 
norepinephrine (NE) against electroshock induced GTC seizures, and 
serotonin (5-HT) against pentylenetetrazole (PTZ) induced absence 
seizures [61], throw some light on the role of neurotransmitters in 
the treatment of seizures, involvement of brain monoamines, mainly 
the NE and dopamine (DA), in mediating the cognitive tasks in 
patients with Alzheimer’s disease. Additionally, several publications 
have provided information on seizures and their treatment, although 
very few attempts have been made to study the effect of drugs on 
memory after seizure inductement, the role of monoamines in 
protection from seizure occurrence and memory impairment, and the 
effect of standard AED treatment on memory. In view of these 
findings, we have chosen curcumin–the active constituent of Curcuma 
longa-which has been claimed to possess effi cacy in the treatment of 
Alzheimer’s disease [62], MAO-A & B inhibitory activity [63] 
enhancement of brain monoamine levels, and rhizomes being cited in 
the database for Indian medicinal plants in the treatment of epilepsy 
[64], for which no reported evidence was available, all these factors 
had made us to focus on the objectives of the present study, to 
evaluate: 1) the protective effect of curcumin on the MES induced 
seizures; 2) effect on memory retention after seizure induction; and 
3) effect on the neurotransmitter levels in various regions of rat 
brain. Epilepsy is a serious and common neurological disease. Nearly 
70% of patients with epilepsy achieve seizure control with 
antiepileptic drugs. Pharmacological treatment of seizures has 
primarily involved modulation of voltage-gated ion channels, 
enhancement of GABAergic inhibition, and reduction of glutamatergic 
excitation [65]. Phytochemical and pharmacological studies have 
been done on anticonvulsant plants, and an increasing number of 
patients use herbal medicines as a supplement to or substitute for 
prescription drugs. Such treatments are considered to be gentle and 
safe alternatives to synthetic drugs [66]. Curcumin, the major 
component of the spice turmeric, can reduce oxidative and 
inflammatory damage [67]. Several studies have shown that 
curcumin has anticonvulsant effects against seizures induced by 
kainic acid (KA) [68] and FeCl3 [69] in rats. We have previously 
shown that high doses (100 and 300 mg/kg, i.p.), but not low doses 
(10 and 30 mg/kg), of curcumin inhibited amygdala-kindled seizures 
in rats [70,71]. The aim of this study was to test the effects of 
curcumin on pilocarpine-induced seizures in rats, to confirm its 
anticonvulsant effects in an additional typical seizure model. Seizures 
can induce the generation of epoxide and free radicals, and this has 
been suggested to contribute to the recurrence of seizures [72]. Lipid 
peroxidation, resulting from an increase in free radicals, causes 
cellular membrane damage, which can also increase the recurrence of 
seizures [73]. Therefore, we also investigated the generation of 
epoxide and free radicals in the hippocampus during pilocarpine-
induced seizures and its modulation by curcumin treatment. 
Curcumin, an active ingredient of turmeric with 
antioxidant and anti-inflammatory properties has recently been 
reported to have anticonvulsant effects in several animal models of 
epilepsy. This study aimed to investigate the effects of curcumin on 
the pilocarpine rat model of status epilepticus. The effect of 
intraperitoneal administration of curcumin (30, 100, and 300 mg/kg) 
on pilocarpine-induced seizures in rats was tested. The correlation 
between seizure activity and hippocampal levels of nitric oxide 
synthase and free radicals was quantified. Whether curcumin 
treatment modulated these parameters was also investigated. 
Curcumin significantly increased seizure threshold at doses of 100 
and 300 mg/kg. Rats with pilocarpineinduced seizures showed 
significantly elevated levels of malonaldehyde, nitric oxide synthase, 
and lactate dehydrogenase, but decreased levels of superoxide 
dismutase and glutathione compared with normal control rats. At 
doses of 100 and 300 mg/kg, curcumin reversed the effects of 
pilocarpine-induced seizures on nitric oxide synthase, lactate 
dehydrogenase, glutathione, and superoxide dismutase. However, 
curcumin did not restore the elevated malonaldehyde levels. 
Curcumin has anticonvulsant activity in the pilocarpine rat model of 
seizures, and that modulation of free radicals and nitric oxide 
synthase may be involved in this effect [74]. 
5.1 Epileptic behaviors 
All the rats in the control group exhibited generalized 
limbic seizures after pilocarpine administration, at a latency of 
minutes. Pretreatment with curcumin significantly delayed the onset 
of seizures at doses of 300 mg/kg and 100 mg/kg compared with 
control. The 30 mg/kg dose of curcumin had no significant effect. 
Similarly, the mean seizure severity score was significantly reduced 
compared with control at curcumin doses of 300 mg/kg and 100 
mg/kg, but not at 30 mg/kg. Pretreatment with curcumin at 300 and 
100 mg/kg also decreased the occurrence of pilocarpine-induced 
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status epilepticus. Several rats died before the onset of status 
epilepticus (2/15 rats treated with 300 mg/kg, 2/15 rats treated with 
100 mg/kg, 4/15 rats treated with 30 mg/kg. In the remaining rats, 
curcumin significantly delayed the onset of status epilepticus at doses 
of 300 mg/kg and 100 mg/kg minutes, compared with control. 
Curcumin at 30 mg/kg did not delay the onset of status epilepticus 
compared with control. 
5.2 Biochemical analysis 
Pilocarpine-induced seizures significantly increased 
malonaldehyde (MDA) content, and treatment with curcumin did not 
normalize this effect. Animals treated with pilocarpine showed an 
elevation in lactate dehydrogenase (LDH) activity that was restored 
by curcumin at 100 or 300 mg/kg. Pilocarpine also caused an 
increase in NOS activity, and curcumin at 100 and 300 mg/kg 
prevented this effect. Both glutathione (GSH) and superoxide 
dismutase (SOD) levels were decreased in pilocarpine-treated rats. 
GSH content was restored to near normal in animals treated with 
curcumin at 100 and 300 mg/kg. Curcumin at 30 mg/kg failed to 
restore SOD activity, but the 100 and 300 mg/kg doses significantly 
increased it towards normal levels. 
 
6. Discussion 
We have demonstrated that pretreatment with curcumin at 
doses of 100 and 300 mg/kg significantly delayed the onset of 
pilocarpine-induced limbic seizures and status epilepticus. These 
doses of curcumin also counteracted pilocarpine-induced changes in 
hippocampal Nitric oxide synthase (NOS), SOD, and LDH activity and 
GSH content. Taken together, these results indicate that the 
anticonvulsant properties of curcumin may at least in part be 
mediated by the central nitric oxide system and free radical 
production. Recent research has shown that curcumin exerted 
anticonvulsant effect against acute generalized seizures induced by 
MES [75], KA [68], and FeCl3 [69], and delayed the development of 
amygdala kindling [70]. These findings suggest that curcumin has 
anticonvulsant activity in a range of models. The mechanisms 
underlying the potential anticonvulsant effects of curcumin are not 
yet fully understood. Previous research has indicated that curcumin 
has antioxidant and anti-inflammatory activity. Epidemiological 
studies showed that curcumin also had antioxidant effects after the 
injury of central nervous system [76]. Curcumin was reported to be 
several times more potent than vitamin E as a free radical scavenger, 
and effective against nitric oxide-based radicals [77]. Oxidative stress 
is known to play a role in epileptogenesis. Free radicals such as 
oxygen, superoxide, and nitrite, are generated during epileptogenesis 
[78]. In lead-induced neurotoxicity in rats, curcumin (100 mg/kg, 
p.o.) has been shown to significantly decrease lipid peroxidation, and 
increase the levels of reduced glutathione and activity of superoxide 
dismutase and catalase [79]. Thus, curcumin is an effective 
antioxidant, and this action may be responsible for its anticonvulsive 
activity. An increase in MDA has been observed in the brain of rats 
with seizures induced by FeCl3 [80] and N-methyl-D-aspartate 
(NMDA) [81]. The MDA level in the hippocampus was also 
significantly increased after pilocarpine-induced seizures. However, 
administration of curcumin could not reverse this effect. Recent 
research has shown that curcumin may trigger intracellular signaling 
responsible for modulation of NMDA receptor function [82] and 
expression of brain-derived neurotrophic factor [83]. Our previous 
research has indicated that curcumin modulates the influx of calcium 
mediated by 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic 
acid (AMPA) and kainate in cultured hippocampal neurons from 
rats.19 Thus, it is likely that the suppression of pilocarpine-induced 
seizures and status epilepticus is associated with modulation of 
neuronal excitability. Curcumin has anticonvulsant potential in the 
pilocarpine model of temporal lobe seizures. Curcumin is abundant, 
inexpensive, and relatively safe in humans. It can cross the blood-
brain barrier and directly exert its effect on the brain [84].  
 
Effects on various phases of GTC seizures 
Treatment with curcumin at doses of 5 mg/kg and 10 
mg/kg exhibited a percentage protection of 50 and 66, respectively. 
Whereas, PHT treated rats showed a 100% protection against the 
MES induced seizures by inhibiting HLTE. Neither of the 2 doses of 
curcumin nor the PHT treated rats had shown any significant changes 
in the duration of tonic flexion and clonic convulsions, but a 
significant reduction was observed in the time taken for the righting 
reflex in curcumin 10 mg/kg and PHT treated rats, respectively. 
Effect on the performance in conditioned avoidance response 
after induction of seizures 
Rats that received MES (epileptic control) exhibited a 
signifi cant decrease in memory retention when compared to the 
control animals (not exposed to MES). Whereas, a significant increase 
in the retention of memory was observed in both the dose levels of 
curcumin. PHT treated rats also had showed a significant 
performance impairment in the conditioned avoidance response. 
Effect on Dopamine, Norepinephrine and Serotonin levels in 
different regions of rat brain: The monoamine levels. 
Effect on brain Dopamine 
A significant decrease in the DA levels were observed in 
cortex, pons, hippocampus and hypothalamus in rats exposed to MES. 
Rats treated with curcumin 5 and 10 mg/kg showed a significant 
increased in DA levels in cortex, pons, hippocampus and 
hypothalamus. PHT treated rats showed a significant increase in 
cortex, hippocampus and hypothalamus. Whereas, no significant 
change was observed in the cerebellum when compared to epileptic 
control (MES) rats. 
Effect on brain Norepinephrine 
A significant decrease in the NE levels of the hippocampus 
and hypothalamus was observed in rats exposed to MES. Curcumin at 
5 and 10 mg/kg showed a significant increase in the NE levels of 
cortex, hippocampus, hypothalamus and pons, respectively, while 
PHT treated rats showed a significant increase in NE levels of the 
cortex, pons and hippocampus. No significant changes were observed 
in the NE levels of cerebellum when compared to epileptic control 
(MES) rats. Values of curcumin (5 & 10 mg/kg) PHT treatments were 
compared with control individually for each phase. 
Effect on brain Serotonin  
A significant decrease in brain serotonin levels were 
observed in cerebellum, hippocampus and hypothalamus of epileptic 
control rats (MES). Curcumin treatment at 5 mg/kg showed an 
increase in the levels of 5-HT in cerebellum, hippocampus and 
hypothalamus. 
Curcumin at doses of 5 mg and 10 mg/kg/p.o. exhibited a 
significant protection against the MES-induced GTC seizures, this 
might be due to the observed increase in the NE and DA levels in 
various parts of the brain substantiating reports that drug treatment 
which increases brain monoamine levels by inhibiting MAO tends to 
raise the seizure threshold [61], as Curcuma longa has been reported 
to increase the brain monoamine levels by inhibiting MAO-A and B in 
mice brain [63]. On the other hand, low concentrations of DA in 
cerebellum had been reported to show an inhibitory effect on 
glutamate, causing blockade of calcium channels, indicating a possible 
mechanism involved in the antiepileptic effect of curcumin, i.e. a 
decreased influx of calcium ions into the neuronal cells, thereby 
inhibiting neurotransmitter re-uptake. This could be effective in the 
treatment of CNS disorders as epileptic depolarizations in single 
motor cortical and hippocampal neurons and focal epileptic 
discharges in neuronal cortical preparations have been reported to be 
decreased by calcium channel blockers. As theoretical considerations 
suggest that calcium channel blockers posses anticonvulsant activity, 
the protective effect of curcumin against MES induced convulsions 
might be due to the decreased calcium influx, resulting in a decrease 
in NE mediated glutamate inhibition. At both the dose levels of 
curcumin, a good memory retentive effect in seizure induced animals 
was observed when compared to the epileptic control and PHT 
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treated rats. This increase in memory retention can be interpreted to 
the increased NE and DA concentrations in brain regions as drugs like 
L-Dopa have shown an improvement in cognitive test of patients of 
Alzheimer’s disease by increasing DA levels. Other possible 
mechanism for the memory retentive effect of curcumin can be 
attributed to the MAO-B inhibitory activity of curcumin [85], as 
selegelline a MAO-B inhibitor has demonstrated mild but significant 
improvement in cognitive tasks in a double blind placebo controlled 
trial in addition to its capacity to increase brain NE and DA 
concentrations [86] and in the treatment of Alzheimer’s disease. 
Pathological abnormalities in serotonergic and noradrenergic 
innervations are known to exist in addition to cholinergic 
innervations in the brain of Alzheimer’s patients. This also indicates 
the rationality of a combination therapy of cholinergic and 
monoaminergic drugs in Alzheimer’s disease, as forebrain 
dopaminergic system is related to cognitive functions. However the 
role of NE and DA on memory retention is also controversial as 
psycho stimulants such as methyl phenidate and amphetamine, which 
are known to increase cerebral catecholamine turnover, have proven 
to be of little value in Alzheimer’s disease [86]. Our studies and the 
data obtained allowed us to substantiate the use of curcumin in 
protection from GTC seizures and enhancing memory. Of particular 
interest are the effects of curcumin on the brain monoaminergic 
system, since it has been suggested that monoamines are of great 




The results of the presented study, that the brain 
monoamines (NE, DA & 5 HT) play an important role in protection 
from epilepsy and memory impairment. The effect of curcumin on 
chemically-induced absence seizures and the effect on the threshold 
for generalized and localized seizures have to be interpreted for 
understanding the anti-epileptic activity of curcumin, and the role of 
monoamines in chemically-induced seizures are to be performed for 
meaningful extrapolations of anti-epileptic activity of curcumin [90-
93]. The curcumin has enormous potential for a variety of diseases. 
Serum levels of curcumin tend to be low, which might be responsible 
for its pharmacological safety and has low bioavailability. Second, the 
tissue concentration of curcumin and how it compares to what is seen 
in cell culture conditions are not known. Some agents such as 
piperine (black pepper) can enhance the bioavailability of curcumin 
through suppression of its glucuronidation occurring primarily in the 
liver and in the intestine. Third, whether there are components of 
turmeric other than curcumin that have beneficial effects either alone 
or in combination with curcumin needs to be determined. For 
instance, numerous activities have been assigned to turmeric oil. 
Fourth, what effect do other spices have on the pharmacology and the 
biology of curcumin needs to be determined. Fifth, structural 
analogues of curcumin that are more bioavailable and efficacious are 
needed. However, this might compromise the safety of curcumin. 
Sixth, well-controlled large clinical trials are required to determine 
the potential of curcumin both in the prevention and therapy of a 
disease. All of these studies should further add to the usefulness of 
curcumin. Overall, the biological safety, combined with its cost and 
efficacy, and thousands of years of experimentation. Curcumin may 
thus be a good supplement to or substitute for antiepileptic drugs. 
Further studies focusing on the mechanism of its antiepileptic effects 
should be conducted. 
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